These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34327767)

  • 1. Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma.
    Johnson PC; Yi A; Horick N; Amonoo HL; Newcomb RA; Lavoie MW; Rice J; Reynolds MJ; Ritchie CS; Nipp RD; El-Jawahri A
    Oncologist; 2021 Nov; 26(11):965-973. PubMed ID: 34327767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes and Health Care Utilization in Patients With Burkitt Lymphoma.
    Johnson PC; Markovitz NH; Yi A; Horick N; Newcomb RA; Cronin K; Schneider D; Nipp RD; El-Jawahri A
    JCO Oncol Pract; 2023 Sep; 19(9):759-766. PubMed ID: 37499211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. End-of-Life Care for Older Adults with Aggressive Non-Hodgkin Lymphoma.
    Johnson PC; Markovitz NH; Yi A; Newcomb RA; Amonoo HL; Nelson AM; Reynolds MJ; Rice J; Lavoie MW; Odejide OO; Nipp RD; El-Jawahri A
    J Palliat Med; 2022 May; 25(5):728-733. PubMed ID: 34724798
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
    Pavlovsky M; Cubero D; Agreda-Vásquez GP; Enrico A; Mela-Osorio MJ; San Sebastián JA; Fogliatto L; Ovilla R; Avendano O; Machnicki G; Barreyro P; Trufelli D; Villanova P
    JCO Glob Oncol; 2022 Mar; 8():e2100265. PubMed ID: 35486884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
    David RJ; Baran A; Loh KP; Casulo C; Barr PM; Friedberg JW; Reagan PM
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):781-787. PubMed ID: 30262330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).
    Tallarico M; Foster JC; Seisler D; Lafky JM; Hurria A; Jatoi A; Cohen HJ; Muss HB; Bartlett N; Cheson BD; Jung SH; Leonard JP; Byrd JC; Nabhan C
    J Geriatr Oncol; 2018 Jul; 9(4):321-328. PubMed ID: 29673807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.
    Morrison VA; Picozzi V; Scott S; Pohlman B; Dickman E; Lee M; Lawless G; Kerr R; Caggiano V; Delgado D; Fridman M; Ford J; Carter WB;
    Clin Lymphoma; 2001 Jun; 2(1):47-56. PubMed ID: 11707870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
    Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
    Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
    Lyman GH; Delgado DJ
    Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
    Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy.
    Iioka F; Izumi K; Kamoda Y; Akasaka T; Ohno H
    Int J Clin Oncol; 2016 Jun; 21(3):498-505. PubMed ID: 26463529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
    Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
    Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
    Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy.
    Huntington SF; Talbott MS; Greer JP; Morgan DS; Reddy N
    Leuk Lymphoma; 2012 Aug; 53(8):1461-8. PubMed ID: 22260160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
    Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
    Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
    Dincol D; Buyukcelik A; Dogan M; Akbulut H; Samur M; Demirkazik A; Senler FC; Onur H; Icli F
    Med Oncol; 2010 Sep; 27(3):942-5. PubMed ID: 19787462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
    Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare utilization and spending among older patients diagnosed with Non-Hodgkin lymphoma.
    Kenzik KM; Williams GR; Bhakta N; Robison LL; Landier W; Goyal G; Mehta A; Bhatia S
    J Geriatr Oncol; 2021 Nov; 12(8):1225-1232. PubMed ID: 34176753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.